Reshma Kewalramani

Reshma Kewalramani became CEO and President of Vertex Pharmaceuticals in April 2020, a physician-scientist who trained as a nephrologist before moving into drug development. Under her leadership, Vertex has evolved from a company defined by a single (albeit extraordinarily successful) franchise in cystic fibrosis into a multi-franchise biotechnology company pushing the boundaries of genetic medicine and pain treatment. Vertex's cystic fibrosis franchise — anchored by Trikafta (known as Kaftrio outside the U.S.) — generates over $9 billion in annual revenue and treats approximately 90% of the CF patient population. This franchise provides an exceptionally stable revenue base with high barriers to biosimilar competition (triple combination therapy with complex manufacturing). However, the limited CF patient population means the franchise will eventually plateau, making pipeline diversification critical. Kewalramani's most groundbreaking achievement was the launch of Casgevy (exa-cel) in late 2023 — the world's first approved CRISPR/Cas9 gene editing therapy, developed in partnership with CRISPR Therapeutics, for treating sickle cell disease and transfusion-dependent beta-thalassemia. Additionally, Vertex's non-opioid pain program (suzetrigine/VX-548, a NaV1.8 inhibitor) has shown promise in clinical trials for acute pain, potentially offering effective pain relief without the addiction risks of opioids. Key stock drivers include CF franchise growth (through label expansions and new patient identification), Casgevy commercial launch trajectory, suzetrigine regulatory approval and launch, kidney disease pipeline, and the sustainability of Vertex's innovation engine.